BIOのチャート
BIOの企業情報
| symbol | BIO |
|---|---|
| 会社名 | Bio-Rad Laboratories Inc （BIO バイオ・ラッド・ラボラトリ―ズ） |
| 分野（sector） | |
| 産業（industry） | |
| 業種 | 医療機器_医療用品_ディストリビュ―タ― 医療関連（Health Care） |
| 概要 | 事業概要 バイオ・ラッド・ラボラトリーズ（Bio-Rad Laboratories Inc.）は複合化学材料及び生物材料の分離またはその成分の識別・分析・浄化に応用される各種製品及びシステムの製造会社である。同社製品は主にライフサイエンス研究、保健及び分析化学等の分野に提供されている。同社はライフサイエンス事業及び臨床診断事業の２つの事業区分により構成される。平成23年12月期決算期において、ライフサイエンス事業及び臨床診断事業の純売上高はそれぞれ同社総純売上高の33%と66%を占めた。平成23年12月期決算期において、ライフサイエンス事業及び臨床診断事業の純売上高はそれぞれ同社の総合純売上高の33%と66%を占めた。平成23年度において、同社の連結売上高の約30％は米国販売事業から、70%は世界中その他市場事業から生じた。平成23年12月31日現在、同社は子会社を通じて、米国以外の35以上の国での直接流通チャネルを所有している。 バイオ・ラッド・ラボラトリ―ズは、米国の医薬品会社。事業は2部門で構成される。ライフサイエンス部門は、実用的なゲノミクス、プロテオミクス、食品安全性の研究に使用される多様な実験用機器、装置、および消耗品の開発、製造、および販売を行う。診断薬部門は、医学的スクリ―ニングおよび診断向けの幅広い製品の開発、製造、販売、およびサポ―トを行う。 Bio-Rad Laboratories, Inc. is a global leader in developing, manufacturing, and marketing a broad range of innovative products for the life science research and clinical diagnostic markets. With a focus on quality and customer service for over 65 years, its products advance the discovery process and improve healthcare. Bio-Rad's customers are university and research institutions, hospitals, public health and commercial laboratories, biotechnology and pharmaceutical companies, as well as applied laboratories that include food safety and environmental quality. Founded in 1952, Bio-Rad is based in Hercules, California, and has a global network of operations with more than 7,800 employees worldwide. Bio-Rad had revenues exceeding $2.5 billion in 2020. |
| 本社所在地 | 510 724-7000 |
| 代表者氏名 | Norman D. Schwartz |
| 代表者役職名 | Chairman of the Board President Chief Executive Officer |
| 電話番号 | +1 510-724-7000 |
| 設立年月日 | 1952年 |
| 市場名 | NYSE（ニューヨーク証券取引所） |
| ipoyear | 年 |
| 従業員数 | 8260人 |
| url | www.bio-rad.com |
| nasdaq_url | |
| adr_tso | |
| EBITDA | EBITDA（百万ドル） 345.37900 |
| 終値（lastsale） | |
| 時価総額（marketcap） | |
| 時価総額 | 時価総額（百万ドル） 9145.17200 |
| 売上高 | 売上高（百万ドル） 2290.10900 |
| 企業価値(EV) | 企業価値(EV)（百万ドル） 8734.24600 |
| 当期純利益 | 当期純利益（百万ドル） 311.99600 |
| 決算概要 | 決算概要 BRIEF: For the fiscal year ended 31 December 2018 Bio-Rad Laboratories Inc. revenues increased 6% to $2.29B. Net income before extraordinary items increased from $52.2M to $312M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Net income benefited from Acquisition Cost decrease from $10M (expense) to $0K Restructuring Charges_Provisions decrease of 90% to $855K (expense). |
BIOのテクニカル分析
BIOのニュース
EASTERLY INVESTMENT PARTNERS LLC Buys 2, Sells 3 in 1st Quarter 2022/08/02 19:00:41 GuruFocus
Related Stocks: NCR , PFE , IBM , BIO , VOD ,
Bio-Rad Laboratories, Inc. (BIO) Management on Q2 2022 Results - Earnings Call Transcript 2022/07/29 01:52:05 Seeking Alpha
Bio-Rad Laboratories, Inc. (NYSE:NYSE:BIO) Q2 2022 Earnings Conference Call July 28, 2022 06:00 PM ET Company Participants Edward Chung - Head of Investor Relations Ilan Daskal - Executive…
Bio-Rad Laboratories: Q2 Earnings Insights 2022/07/28 22:00:21 Benzinga
Bio-Rad Laboratories (NYSE: BIO ) reported its Q2 earnings results on Thursday, July 28, 2022 at 04:00 PM. Here''s what investors need to know about the announcement. Earnings Bio-Rad Laboratories beat estimated earnings by 20.71%, reporting an EPS of $3.38 versus an … Full story available on Benzinga.com
Bio-Rad Labs Non-GAAP EPS of $3.38 beats by $0.67, revenue of $691.1M beats by $26.5M 2022/07/28 20:50:37 Seeking Alpha
Bio-Rad Labs press release (BIO): Q2 Non-GAAP EPS of $3.38 beats by $0.67.Revenue of $691.1M (-3.5% Y/Y) beats by $26.5M.For the full-year 2022, the company now anticipates…
Bio-Rad Reports Second-Quarter 2022 Financial Results 2022/07/28 20:17:00 Wallstreet:Online
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader in life science research and clinical diagnostic products, today announced financial results for the second quarter ended June 30, 2022. Second-quarter 2022 net sales were $691.1 million, a decrease of 3.5 percent compared to $715.9 million reported for the second quarter of 2021. COVID-related revenue was approximately $33 million
Bio-Rad Laboratories, Inc. (BIO) Management on Q2 2022 Results - Earnings Call Transcript 2022/07/29 01:52:05 Seeking Alpha
Bio-Rad Laboratories, Inc. (NYSE:NYSE:BIO) Q2 2022 Earnings Conference Call July 28, 2022 06:00 PM ET Company Participants Edward Chung - Head of Investor Relations Ilan Daskal - Executive…
Bio-Rad Laboratories: Q2 Earnings Insights 2022/07/28 22:00:21 Benzinga
Bio-Rad Laboratories (NYSE: BIO ) reported its Q2 earnings results on Thursday, July 28, 2022 at 04:00 PM. Here''s what investors need to know about the announcement. Earnings Bio-Rad Laboratories beat estimated earnings by 20.71%, reporting an EPS of $3.38 versus an … Full story available on Benzinga.com
Bio-Rad Labs Non-GAAP EPS of $3.38 beats by $0.67, revenue of $691.1M beats by $26.5M 2022/07/28 20:50:37 Seeking Alpha
Bio-Rad Labs press release (BIO): Q2 Non-GAAP EPS of $3.38 beats by $0.67.Revenue of $691.1M (-3.5% Y/Y) beats by $26.5M.For the full-year 2022, the company now anticipates…
Bio-Rad Reports Second-Quarter 2022 Financial Results 2022/07/28 20:17:00 Wallstreet:Online
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader in life science research and clinical diagnostic products, today announced financial results for the second quarter ended June 30, 2022. Second-quarter 2022 net sales were $691.1 million, a decrease of 3.5 percent compared to $715.9 million reported for the second quarter of 2021. COVID-related revenue was approximately $33 million
Bio-Rad Labs Q2 2022 Earnings Preview (NYSE:BIO) 2022/07/27 21:35:19 Seeking Alpha
Bio-Rad Labs (BIO) is scheduled to announce Q2 earnings results on Thursday, July 28th, after market close.The consensus EPS Estimate is $2.71 (-23.4% Y/Y) and the consensus…
AmericaFirst Defensive Growth Fund Buys HCA Healthcare Inc, Bio-Rad Laboratories Inc, Pfizer ... 2021/12/08 20:38:02 GuruFocus
Related Stocks: HCA , BIO.B , PFE , PKI , TDY , HOLX , IDXX , MNST , EPC , UVV , HSIC , TECH , PRMW , BTI ,
Bacterial and Plasmid Vectors Global Market Report 2021 Featuring Sigma-Aldrich, ATUM, QIAGEN, Promega, Thermo Fisher Scientific, GenScript Biotech, Takara Bio, IBA, Bio-Rad Labs, New England Biolabs - ResearchAndMarkets.com 2021/12/08 13:56:00 Business Wire
DUBLIN--(BUSINESS WIRE)--The "Bacterial and Plasmid Vectors Global Market Report 2021: COVID-19 Growth and Change to 2030" report has been added to ResearchAndMarkets.com''s offering. The global bacterial & plasmid vectors market is expected to grow from $0.34 billion in 2020 to $0.39 billion in 2021 at a compound annual growth rate (CAGR) of 14.7%. The market is expected to reach $0.68 billion in 2025 at a CAGR of 15%. Major players in the bacterial & plasmid vectors market are Sigma-Al
Chromatography Data Systems (CDS) Market Emerging Trends by Top Key Players Advanced Chemistry Development, DataApex, Agilent Technologies, Inc., Bio-Rad Laboratories Inc 2021/12/08 12:18:12 OpenPR
Chromatography system (CDS) is that the software package program, that automates instrument management, information acquisition, processing, information filtering, information storage, and direction in varied natural process systems like Gas natural process (GC), High Performance Liquid natural process (HPLC), critical Fluid
Laboratory Supplies Market Emerging Trends, Reviews, and Regional Outlook Study 2020 2030 | Bruker Corporation, Bio-Rad Laboratories, Inc.,, Shimadzu Corporation, Waters Corporation 2021/12/08 05:37:41 OpenPR
Laboratory Supplies Market: Overview The laboratory supplies market is estimated to gain tremendous growth prospects across the assessment period of 2020-2030. The growing demand for laboratory products on the back of the advancements in the chemical and biological research field will
Global Point of care Diagnostics Market Size [2021-2028] | to Reach USD 36.21 Billion by 2028 2021/12/07 08:52:00 Intrado Digital Media
Key Players Covered in the Point of Care Diagnostics Market Research Report Are F. Hoffmann-La Roche Ltd (Basel, Switzerland), Thermo Fisher Scientific Inc. (Massachusetts, U.S.), Abbott Laboratories (Illinois, U.S), Quest Diagnostics Incorporated (New Jersey, United States), BD (Franklin Lakes, U.S), bioMérieux SA (Marcy l''Etoile, France), Cardinal Health, Inc. (Ohio, U.S), Mesa Biotech (California, U.S), Cepheid (California, U.S), Trinity Biotech (Bray, Ireland), Quidel Corporation (San Diego, U.S.), Bio-Rad Laboratories Inc. (California, U.S) and other key market players Key Players Covered in the Point of Care Diagnostics Market Research Report Are F. Hoffmann-La Roche Ltd (Basel, Switzerland), Thermo Fisher Scientific Inc. (Massachusetts, U.S.), Abbott Laboratories (Illinois, U.S), Quest Diagnostics Incorporated (New Jersey, United States), BD (Franklin Lakes, U.S), bioMérieux SA (Marcy l''Etoile, France), Cardinal Health, Inc. (Ohio, U.S), Mesa Biotech (California, U.S), Cepheid (California, U.